Zur Kurzanzeige

Einfluss der kombinierten Freisetzung von rhBMP-2 und rhVEGF165 aus PDLLA/Calciumcarbonat-Gerüsten auf die In-vitro-Aktivität der Osteogenese und Angiogenese

dc.contributor.advisorSchliephake, Henning Prof. Dr. Dr.
dc.contributor.authorBoven, Johanna Margaretha
dc.date.accessioned2018-05-28T09:11:08Z
dc.date.available2018-06-18T22:50:16Z
dc.date.issued2018-05-28
dc.identifier.urihttp://hdl.handle.net/11858/00-1735-0000-002E-E3F8-0
dc.identifier.urihttp://dx.doi.org/10.53846/goediss-6891
dc.identifier.urihttp://dx.doi.org/10.53846/goediss-6891
dc.language.isodeude
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc610de
dc.titleEinfluss der kombinierten Freisetzung von rhBMP-2 und rhVEGF165 aus PDLLA/Calciumcarbonat-Gerüsten auf die In-vitro-Aktivität der Osteogenese und Angiogenesede
dc.typedoctoralThesisde
dc.title.translatedInfluence of the combined release of rhBMP-2 and rhVEGF165 from PDLLA /calcium carbonate scaffolds on the in vitro activity of osteogenesis and angiogenesisde
dc.contributor.refereeMiosge, Nicolai Prof. Dr.
dc.date.examination2018-06-11
dc.description.abstractengThe replacement of bony structures is part of the clinical routine of oral and maxillofacial surgery. The choice of method and substitute material depends on several factors: the current and long-term mechanical strength of the material, the availability, the technical complexity, the costs, the patient's morbidity, the complication rate and the total duration of treatment. For this reason, the search for the ideal bone replacement material is of great importance. The aim of the study is to derive from these results an improvement of the composite material with regard to the physiological and economic clinical application. The present work deals with the further development of a resorbable poly-D-L-lactide material of synthetic origin. The granules of amorphous poly-D, L-lactic acid (PDLLA) required for the manufacture of the implant frameworks were mixed with nanocrystals of amorphous carbonate-containing calcium phosphate (CaCO 3, 12 μm) in a mixing ratio of 1: 4. The purely osteoconductive properties are to be expanded by loading with osteoinductive cytokines. For this, recombinant human BMP-2 (200 µg/g, 400 µg/g, 800 µg/g, 1600 µg/g, 0 µg/g BMP-2), recombinant human VEGF165 (4 µg/g, 25 µg/g, 100 µg/g and 400µg/g, 0 µg/g VEGF165) and their combination (800 µg/g / 100 µg/g, 800 µg/g / 25 µg/g, 400 µg/g / 100 µg/g, 400 µg/g / 25 µg/g ,0 µg/g / 0 µg/g BMP-2 / VEFG165) were mixed with the granulate and pressed into a cylindrical polymer body (8mm diameter x 3mm hight) by a hypercritical CO2 foaming process. In a first experiment, the release kinetics of the incorporated factors alone and their combination should be investigated by ELISA tests over a period of 648 hours at 12 different times (1h, 12h,24h, 72h, 144h, 216h, 288h, 360h, 432h, 504h, 576h, 648h). Implants loaded with BMP-2 alone and in combination with VEGF165 were dissolved in DMEM-solution, implants loaded with VEGF alone and their combinations with BMP-2 were dissolved in EGM-2 solution. Here, concentration- and combination dependent differences of the release kinetics should be compared. In a second experiment, the biological activity of the factors should be tested in vitro on established cell lines. The biological activity of the released rhBMP-2 was measured by the induction of alkaline phosphatase in C2C12 cells. The biological activity of the released rhVEGF165 was determined by stimulating the proliferation of HUVEC cells. Overall, the PDLLA / calcium carbonate polylactide material tested in the present study provides a release pattern consistent with the prior art of cytokine secreted during bone healing, whether incorporated alone or in combination. The combination of factors showed significantly altered results in terms of percent release within the observation period in both groups. The biological activity of rhBMP-2 and rhVEGF165 was ensured. The combination of both factors led to an improvement in the results in the biological tests.de
dc.contributor.coRefereeMausberg, Rainer Prof. Dr.
dc.subject.engPDLLAde
dc.subject.engBMP-2de
dc.subject.engVEGF165de
dc.identifier.urnurn:nbn:de:gbv:7-11858/00-1735-0000-002E-E3F8-0-7
dc.affiliation.instituteMedizinische Fakultätde
dc.subject.gokfullMedizin (PPN619874732)de
dc.description.embargoed2018-06-18
dc.identifier.ppn1023361035


Dateien

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige